<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251026</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-E-0002</org_study_id>
    <secondary_id>2019-004909-27</secondary_id>
    <nct_id>NCT04251026</nct_id>
  </id_info>
  <brief_title>A Study of DNL310 in Pediatric Participants With Hunter Syndrome</brief_title>
  <official_title>A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics&#xD;
      (PK), and pharmacodynamics (PD) of DNL310, an investigational central nervous system&#xD;
      (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and&#xD;
      CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).&#xD;
&#xD;
      The study has three cohorts:Cohort A will enroll participants with neuronopathic MPS II aged&#xD;
      5 to 10 years; Cohort B will enroll participants with MPS II, either neuronopathic or&#xD;
      non-neuronopathic, aged 2 to 18 years; and Cohort C will enroll participants with&#xD;
      neuronopathic MPS II aged ≥2 and &lt;4 (Cohort C can include nMPS II participants ≥4 if the&#xD;
      participant is a sibling of a participant aged ≥2 and &lt;4).&#xD;
&#xD;
      Participants, whose physicians feel they are deriving benefit, will have the opportunity to&#xD;
      be reconsented into a safety extension for continued evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of infusion-related reactions (IRRs)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urine total glycosaminoglycan (GAG) concentrations</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in concomitant medications</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cerebrospinal fluid (CSF) of heparan sulfate</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Trough concentration (Cmin) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (tmax) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to infinity (AUC∞) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve over a dosing interval (AUCτ) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent terminal elimination half-life (t½) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of immunogenicity of DNL310 in serum, as measured by the incidence of anti-drug antibodies (ADAs) relative to baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine concentration of heparan sulfate (HS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A consistent dose level in participants with neuronopathic MPS II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL310</intervention_name>
    <description>Intravenous weekly administration</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of MPS II&#xD;
&#xD;
          -  Cohort A: Participants aged 5 to 10 years with neuronopathic MPS II&#xD;
&#xD;
          -  Cohort B: Participants aged 2 to 18 years with non-neuronopathic MPS II, neuronopathic&#xD;
             MPS II, or unknown phenotype&#xD;
&#xD;
          -  Cohort C: Participants aged ≥2 to &lt;4 years with neuronopathic MPS II (this cohort can&#xD;
             include participants ≥4 years of age if participant is a sibling of a participant ≥2&#xD;
             to &lt;4 years of age)&#xD;
&#xD;
          -  For participants receiving intravenous iduronate 2-sulfatase (IDS) ERT, tolerated a&#xD;
             minimum of 4 months of therapy during the period immediately prior to screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Unstable or poorly controlled medical condition(s) or significant medical or&#xD;
             psychological comorbidity or comorbidities that, in the opinion of the investigator,&#xD;
             would interfere with safe participation in the trial or interpretation of study&#xD;
             assessments&#xD;
&#xD;
          -  Use of any CNS-targeted MPS II ERT within 3 months before study start for participants&#xD;
             aged ≥5 years, and within 6 months before study start for participants aged &lt;5 years.&#xD;
&#xD;
          -  Use of IDS gene therapy or stem cell therapy at any time&#xD;
&#xD;
          -  Clinically significant thrombocytopenia, other clinically significant coagulation&#xD;
             abnormality, or significant active bleeding, or required treatment with an&#xD;
             anticoagulant or more than two antiplatelet agents&#xD;
&#xD;
          -  Contraindication for lumbar punctures&#xD;
&#xD;
          -  Have a clinically significant history of stroke, status epilepticus, head trauma with&#xD;
             loss of consciousness, or any CNS disease that is not MPS II-related within 1 year of&#xD;
             screening&#xD;
&#xD;
          -  Have had a ventriculoperitoneal (VP) shunt placed, or any other brain surgery, or have&#xD;
             a clinically significant VP shunt malfunction within 30 days of screening&#xD;
&#xD;
          -  Have any clinically significant CNS trauma or disorder that, in the opinion of the&#xD;
             investigator, may interfere with assessment of study endpoints or make participation&#xD;
             in the study unsafe&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Bakardjiev, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials at Denali Therapeutics</last_name>
    <phone>Email:</phone>
    <email>clinical-trials@dnli.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Melton</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>4785</phone_ext>
      <email>esther.melton@ucsf.edu</email>
    </contact>
    <contact_backup>
      <email>paul.harmatz@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Harmatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Krasowski</last_name>
      <phone>312-227-8953</phone>
      <email>mkrasowski@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Burton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Children's Research Institue</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Zhu</last_name>
      <phone>919-966-1447</phone>
      <email>czhu@email.unc.edu</email>
    </contact>
    <contact_backup>
      <email>muenzer@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Muenzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC | Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Kolar</last_name>
      <phone>412-692-8343</phone>
      <email>kolardr@upmc.edu</email>
    </contact>
    <contact_backup>
      <email>rajands@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deepa Soundara Rajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>South Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Hardon</last_name>
    </contact>
    <contact_backup>
      <phone>0031-6-36115443</phone>
      <email>j.hardon@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ans T Van der Ploeg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS II</keyword>
  <keyword>Hunter Syndrome</keyword>
  <keyword>nMPS II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

